Fortnightly Review: Impotence: Diagnosis and management of male erectile dysfunction

BMJ

Volumn 308, Issue 6934, 1994, Pages 957-

  Kirby, R S ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; PAPAVERINE; PHENOXYBENZAMINE; PHENTOLAMINE; PROSTAGLANDIN E1;

HUMAN; IMPOTENCE; MALE; MALE INFERTILITY; PATIENT COUNSELING; PENIS ERECTION; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW;

HUMAN; IMPOTENCE; MALE; PAPAVERINE; PENILE ERECTION; PENIS; PHYSICAL EXAMINATION; RISK FACTORS; SEX COUNSELING;

EID: 0028262486     PISSN: 09598138     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.308.6934.957     Document Type: Article

References (36)

1. Furlow WL. Prevalence of impotence in the United States. Medical Aspects of Human Sexuality 1985; 19: 13–6.
2. McCulloch DK Campbell IW Wu FC Prescott RJ Clarke BF. The20prevalence of diabetic impotence. Diabetologia 1980; 18: 279–83.
3. Lerner SE Melman A Christ GJ. Review of erectile dysfunction: New insights and more questions. J Urol 1993; 149: 1246–55.
4. Lue TF Tanagho EA. Physiology of erection and pharmacological20management of impotence. J Urol 1987; 137: 829–36.
5. Batra AK Lue TF. Penile erection: circulatory physiology. In: Kirby RSCarson CWebster GDeds. Impotence: diagnosis and management. Oxford: Butterworth-Heinemann, 1991: 19–26.
6. Krane RJ Goldstein I Saenz De Tejada I. Medical progress: impotence. N Engl J Med 1989; 321: 1648–59.
7. Franks S Jacobs HS Martin N Nabarro JD. Hyperprolactinaemia and impotence. Clin Endocrinol 1978; 8: 277–87.
8. Troy K Cuttner J Reilly M Grabowski G Desnick: R. Tartrate-resistant acid phosphatase staining of monocytes in Gaucher disease. Am J Hematol 1985; 19: 237–44.
9. Michael V. Arterial disease as a cause of impotence. Clin Endocrinol Metab 1982; 11: 725–48.
10. Medical Research Council Working Party. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1981; ii: 539–43.
11. Treatment of Mild Hypertension Research Group. A randomized, placebocontrolled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 1991; 151: 1413–23.
12. Karacan I. Clinical value of nocturnal erection in the prognosis and diagnosis20of impotence. Medical Aspects of Human Sexuality 1970; 4: 27–34.
13. Ek A Bradley WE Krane RJ. Nocturnal penile rigidity measured by the snapgauge band. J Urol 1983; 129: 964–6.
14. Eardley I Kirby RS Fowler CJ. Neurophysiological testing. In: Kirby RSCarson CWebster GDed. Impotence: diagnosis and management. Oxford: Butterworth-Heinemann, 1991: 109–16.
15. Lue TF Hricak H Marich KW Tanagho EA. Vasculogenic impotence evaluated by high resolution ultrasonography and pulsed Doppler spectrum analysis. Radiology 1985; 155: 777–81.
16. Amin Z Patel U Freidman EP Vale JA Kirby RS Less WR. Colour Doppler and duplex ultrasound assessment of Peyronie's disease in impotent men. Br J Radiol 1993; 66: 398–402.
17. Bookstein JJ Valji K Parsons L Kessler W. Pharmacoarteriography in20the evaluation of impotence. J Urol 1987; 137: 333–7.
18. Kirby RS Eardley I. Medical treatment of erectile dysfunction. In: Kirby RSCarson CWebster GDeds. Impotence: diagnosis and management. Oxford: Butterworth-Heinemann, 1991: 149–52.
19. Susset JG Tessier CD Wincze J Bansal S Malhotra C Schwacha MG. Effect of yohimbine hydrochloride on erectile impotence: A double-blind study. J Urol 1989; 141: 1360–3.
20. Reid K Sturridge DHC Morales A Condra M Harris C Owen J Fenemore J. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 1987; ii: 421–3.
21. Wilson JD Griffin JE. The use and misuse of androgens. Metabolism 1980; 29: 1278–95.
22. Bancroft J Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983; 12: 59–62.
23. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982; ii: 938.
24. Brindley GS. Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br J Pharmacol 1986; 87: 495–500.
25. Padma-Nathan H Goldstein I Payton T Krane RJ. Intracavernosal pharmacotherapy: The pharmacologic erection program. World J Urol 1987; 5: 160 -5.
26. Hollander JB Gonzalez J Norman T. Patient satisfaction with pharmacologic erection program. Urology 1992; 39: 439–41.
27. Stackl W Hasun R Marberger M. Intracavernous injection of prostaglandin E1 in impotent men. J Urol 1988; 140: 66–8.
28. Lee LM Stevenson RW Szasz G. Prostaglandin E1 versus phentolamine/ papaverine for the treatment of erectile impotence: a double- blind comparison. J Urol 1988; 141: 54–7.
29. Djamilian M Stief CG Kuczyk M Jonas U. Follow up results of combination of calcitonin gene-related peptide and prostaglandin E1 in treatment of erectile dysfunction. J Urol 1993; 149: 1296–8.
30. Andersson KE Holmquist F Wagner G. Pharmacology of drugs used for treatment of erectile dysfunction and priapism. International Journal of Impotence Research 1991; 3: 155–72.
31. Von Heyden B Donatucci CF Kaula N Lue TF.Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.J Urol201993;149:1288 -90.
32. Wespes E Schulman C. Venous impotence: pathophysiology, diagnosis and treatment. J Urol 1993; 149: 1238–45.
33. Goldstein I. Arterial revascularisation procedures. Sem Urol 1986; 4: 252–8.
34. Wilson SK Wahman GE Lange JL. Eleven years' experience with the inflatable penile prosthesis. J Urol 1988; 139: 951–2.
35. Malloy TR Wein AJ Carpiniello VL. Reliability of AMS M700 inflatable penile prosthesis. Urology 1986; 28: 385–7.
36. Witherington R. Vacuum constriction device for management of erectile impotence. J Urol 1989; 141: 320–2.